Vimarsana
Biggest News Aggregation in the World

Page 4 - Dan Ferry News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dan Ferry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dan Ferry Today - Breaking & Trending Today

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline - Vimarsana News

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
CorMedix Inc Common Stock (CRMD) Q2 2022 Earnings Call Transcript - Vimarsana News

CorMedix Inc Common Stock (CRMD) Q2 2022 Earnings Call Transcript

CRMD earnings call for the period ending June 30, 2022.

Source: fool.com
Diplomat Ryabokon: Russia can proportionally respond to Lithuania's restriction of transit - Vimarsana News

Diplomat Ryabokon: Russia can proportionally respond to Lithuania's restriction of transit

Russia has the opportunity to proportionally respond to the restriction of transit to the Kaliningrad region by Lithuania. Sergei Ryabokon, Charge d'Affaires of Russia in Vilnius, stated this on the air of the Russia 24 TV channel.

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript - Vimarsana News

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript

Medicenna Therapeutics Corp. (NASDAQ:NASDAQ:MDNA) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President...

Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study - Vimarsana News

Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study

-- Peak CD8+ T cell / Treg ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts -- MDNA11-induced increases in CD8+ T and NK... | December 22, 2021